查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球循环肿瘤细胞 (CTC) 市场
市场调查报告书
商品编码
1380251

2023-2030 年全球循环肿瘤细胞 (CTC) 市场

Global Circulating Tumor Cells (CTC) Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 195 Pages | 商品交期: 2-3个工作天内

价格

细分市场前景

全球循环肿瘤细胞市场按技术、产品和最终用户进行细分。根据技术，市场细分为 CTC 检测和富集方法、CTC 直接检测方法和 CTC 分析。根据产品，市场细分为试剂盒和试剂、采血管和设备。此外，根据最终用户，市场细分为医院和诊所、研究和学术机构以及诊断中心。其中，由于奈米技术的发展，CTC检测和富集方法子领域预计将占据相当大的市场份额，功能化奈米材料修饰的微流控晶片广泛应用于CTC的富集和检测。

预计试剂盒和试剂细分市场将在全球循环肿瘤细胞市场中占据相当大的份额

其中，试剂盒和试剂细分市场预计将在全球循环肿瘤细胞（CTC）市场中占据相当大的份额。分段增长归因于非侵入性培养基试剂盒和试剂在癌症检测中日益增长的影响力。来自个别患者的肿瘤细胞—透过使研究人员能够更好地模拟疾病并预测患者对体外治疗的反应，有望帮助提高临床试验的成功率。该公司的新型现成模组化肿瘤培养基套件旨在使研究人员更容易获得复杂的癌症模型。例如，2023 年6 月，赛默飞世尔科技(Thermo Fisher Scientific) 在服务科学领域推出了Gibco (TM) OncoPro (TM) 肿瘤培养基试剂盒*，这是第一个专门为扩增患者来源的肿瘤或癌症而开发的商用培养基来自多种癌症适应症的类器官。

区域展望

全球循环肿瘤细胞市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于采用了有效的诊断工具，预计亚太地区将保持相当大的CAGR作为基于CTC 的测试和非侵入性循环肿瘤诊断方法，主要市场参与者包括AnchorDx、Burning Rock Biotech Ltd.、Exact Sciences Corp.、Guardant Health、Otsuka Pharmaceutical Co., Ltd. 等。

北美地区预计将在全球循环肿瘤细胞市场中占据主导地位

在所有地区中，预计北美地区在预测期内将拥有最大的市场份额。区域成长归因于庞大的患者群体、关键参与者的强大存在、药品的便利性、发达的医疗基础设施、医疗保健系统中有利的报销政策、更多的研究、开发和创新活动以及更多地采用先进的循环肿瘤细胞（CTC）技术。区域增长归因于癌症患者的增加。

根据美国癌症协会（ACS）统计，2023年1月，约有238,340例新发生肺癌病例（男性117,550例，女性120,790例），因肺癌死亡约127,070例（男性67,160例，女性59,910例） 。该地区主要市场参与者的投资增加，以及主要参与者采用各种策略的增加，预计将增加市场机会。主要市场参与者包括 Advanced Cell Diagnostics、Bio-Rad Laboratories, Inc.、Epic Sc​​iences、Ikonisys Inc.、Illumina, Inc. 等。

市场参与者展望

服务循环肿瘤细胞市场的主要公司包括： Bio-Rad Laboratories, Inc.、Illumina, Inc.、Johnson & Johnson、QIAGEN NV、Thermo Fisher Scientific Inc.等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2020 年 10 月，Epic Sc​​iences, Inc. 和 Predicine, Inc. 建立了全球策略合作伙伴关係，为生物製药公司提供 Predicine 基于 ctDNA 的测试和 Epic 基于 CTC 的测试。 Epic 以 CTC 为基础的平台提供 AR-V7、AR-N term、PSMA、ER、PR 和其他表型测试的测试。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 在全球循环肿瘤细胞市场中营运的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Bio-Rad Laboratories, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • QIAGEN NV
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Thermo Fisher Scientific Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Johnson & Johnson Service Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Illumina, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按技术分類的全球循环肿瘤细胞市场
    • CTC 检测和富集方法
    • CTC直接检测方法
    • CTC分析
  • 全球循环肿瘤细胞市场（按产品）
    • 试剂盒和试剂
    • 采血管
    • 装置
  • 最终用户的全球循环肿瘤细胞市场
    • 医院和诊所
    • 诊断中心
    • 研究和学术机构

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Advanced Cell Diagnostics
  • Akadeum Life Sciences, Inc.
  • BIOCEPT, Inc.
  • BioFluidica, Inc.
  • Biolidics Ltd.
  • Creativ MicroTech, Inc.
  • Epic Sciences
  • Fluxion Biosciences, Inc.
  • Ikonisys Inc.
  • LineaRx, Inc. (Applied DNA Sciences)
  • LungLife AI, Inc.
  • Menarini Silicon Biosystems
  • Miltenyi Biotec
  • OncoDiscover
  • Precision Medicine Group, LLC.
  • Sysmex Corporation
  • ScreenCell
  • STEMCELL Technologies, Inc.
Product Code: OMR2027752

Title: Global Circulating Tumor Cells Market Size, Share & Trends Analysis Report by Technology (CTC Detection and Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis), by Product (Kits and Reagents, Blood Collection Tubes and Devices), and by End Users (Hospitals and Clinics, Research and Academic Institutes and Diagnostic Centers),Forecast Period (2023-2030).

Global circulating tumor cells market is anticipated to grow at a CAGR of 12.5% during the Forecast Period (2023-2030). Circulating tumor cells (CTC) provide a blood biomarker for early carcinogenesis, cancer progression, and treatment effectiveness. The growing adoption of CTC assays has attracted intense interest as a biomarker that may assist in disease management and is acting as a key supporting factor for the growth of the market globally. Various test offers physicians the ability to serially monitor their patients' response to treatment, especially for circulating tumor monitoring assay, using a simple blood draw, and using those insights to make informed decisions for future care. Hence, the market players are also focusing on introducing circulating tumor cell-based monitoring assays that further bolster market growth. For instance, in January 2023, Foundation Medicine, Inc., in molecular profiling for cancer, and Natera, Inc., in cell-free DNA testing, launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Segmental Outlook

The global circulating tumor cells market is segmented on the technology, product, and end users. Based on the technology, the market is sub-segmented into CTC detection and enrichment methods, CTC direct detection methods, and CTC analysis. Based on the product, the market is sub-segmented into kits and reagents, blood collection tubes, and devices. Further, based on end users, the market is sub-segmented into hospitals and clinics, research and academic institutes, and diagnostic centers. Among the technology, the CTC detection and enrichment methods sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of nanotechnology, microfluidic chips modified with functionalized nanomaterials which are widely used in the enrichment and detection of CTCs.

The Kits and Reagents Sub-Segment is Anticipated to Hold a Considerable Share of the Global Circulating Tumor Cells Market

Among the products, the kits and reagents sub-segment is expected to hold a considerable share of the global circulating tumor cells (CTC) market. The segmental growth is attributed to the growing influence of the non-invasive culture medium kit and reagents in the detection of cancer. Tumor cells derived from individual patients - hold promise in helping improve clinical trial success rates by enabling researchers to better model disease and predict patient response to therapeutics in vitro. Companies' new off-the-shelf, modular tumoroid culture medium kit is designed to make complex cancer models more accessible to researchers. For instance, in June 2023, Thermo Fisher Scientific, in serving science, launched the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.

Regional Outlook

The global circulating tumor cells market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a considerable CAGR owing to the adoption of effective diagnostic tools such as CTC-based tests and non-invasive methods for the diagnosis of circulating tumors. The key market players include AnchorDx, Burning Rock Biotech Ltd., Exact Sciences Corp., Guardant Health, Otsuka Pharmaceutical Co., Ltd., and others.

The North America Region is Expected to Dominant in the Global Circulating tumor cells Market

Among all regions, the North American region is anticipated to have the largest market share over the forecast period. Regional growth is attributed to the presence of a large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, a higher number of researches, development, & innovation activities and higher adoption of advanced circulating tumor cells (CTC) technology. Regional growth is attributed to an increase in cancer patients.

According to the American Cancer Society (ACS), in January 2023, About 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 mortality from lung cancer (67,160 in men and 59,910 in women). The rise in investment by key market players in the region, along with the rise in the adoption of various strategies by the key players is anticipated to increase opportunities in the market. The key market players include Advanced Cell Diagnostics, Bio-Rad Laboratories, Inc., Epic Sciences, Ikonisys Inc., Illumina, Inc., and others.

Market Players Outlook

The major companies serving the circulating tumor cells market include: Bio-Rad Laboratories, Inc., Illumina, Inc., Johnson & Johnson, QIAGEN N.V., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, Epic Sciences, Inc. and Predicine, Inc. entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine's ctDNA-based testing and Epic's CTC-based testing. Epic's CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR, and other phenotypic tests.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global circulating tumor cells market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bio-Rad Laboratories, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. QIAGEN N.V.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Johnson & Johnson Service Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Illumina, Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Circulating Tumor Cells Market by Technology
    • 4.1.1. CTC Detection and Enrichment Methods
    • 4.1.2. CTC Direct Detection Methods
    • 4.1.3. CTC Analysis
  • 4.2. Global Circulating Tumor Cells Market by Product
    • 4.2.1. Kits and Reagents
    • 4.2.2. Blood Collection Tubes
    • 4.2.3. Devices
  • 4.3. Global Circulating Tumor Cells Market by End Users
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research and Academic Institutes

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Cell Diagnostics
  • 6.2. Akadeum Life Sciences, Inc.
  • 6.3. BIOCEPT, Inc.
  • 6.4. BioFluidica, Inc.
  • 6.5. Biolidics Ltd.
  • 6.6. Creativ MicroTech, Inc.
  • 6.7. Epic Sciences
  • 6.8. Fluxion Biosciences, Inc.
  • 6.9. Ikonisys Inc.
  • 6.10. LineaRx, Inc. (Applied DNA Sciences)
  • 6.11. LungLife AI, Inc.
  • 6.12. Menarini Silicon Biosystems
  • 6.13. Miltenyi Biotec
  • 6.14. OncoDiscover
  • 6.15. Precision Medicine Group, LLC.
  • 6.16. Sysmex Corporation
  • 6.17. ScreenCell
  • 6.18. STEMCELL Technologies, Inc.

LIST OF TABLES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CTC ANALYSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 19. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CIRCULATING TUMOR CELLS MARKET RESEARCH AND ANALYSIS BY END USERS, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 2. GLOBAL CTC DETECTION AND ENRICHMENT METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CTC DIRECT DETECTION METHODS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CTC ANALYSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 6. GLOBAL CIRCULATING TUMOR CELLS KITS AND REAGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL CIRCULATING TUMOR CELLS BLOOD COLLECTION TUBES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CIRCULATING TUMOR CELLS DEVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY END USERS, 2022 VS 2030 (%)
  • 10. GLOBAL CIRCULATING TUMOR CELLS FOR HOSPITALS and CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CIRCULATING TUMOR CELLS FOR RESEARCH AND ACADEMIC INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CIRCULATING TUMOR CELLS FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CIRCULATING TUMOR CELLS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. LATIN AMERICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. MIDDLE EAST AND AFRICA CIRCULATING TUMOR CELLS MARKET SIZE, 2022-2030 ($ MILLION)